Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

Overview

Journal JTO Clin Res Rep

Date 2024 Apr 8

PMID 38586301

Authors

Frank Griesinger

Martin Sebastian

Wolfgang M Brueckl

Horst-Dieter Hummel

Bastian Jaeschke

Jens Kern

Claas Wesseler

Martina Janicke

Annette Fleitz

Stefan Zacharias

Annette Hipper

Annika Groth

Wilko Weichert

Steffen Dorfel

Volker Petersen

Jan Schroder

Jochen Wilke

Wilfried E E Eberhardt

Michael Thomas

Affiliations

Soon will be listed here.

Abstract

Introduction: Patients with metastatic NSCLC (mNSCLC) treated with immune checkpoint inhibitors in clinical practice may often not meet the strict inclusion criteria of clinical trials. Our aim was to assess the trial eligibility of patients with mNSCLC treated with pembrolizumab monotherapy in real-world and to compare the outcome of "trial-ineligible" and "potentially trial-eligible" patients.

Methods: Data from the prospective, clinical research platform CRISP were used to compare patient characteristics, treatment, and outcome of patients with programmed cell death-ligand 1 tumor proportion score greater than or equal to 50% tumors treated with pembrolizumab monotherapy who are deemed either "potentially trial-eligible" or "trial-ineligible" according to inclusion and exclusion criteria of the registrational studies (KEYNOTE-024 and -042).

Results: Of 746 patients included, 343 patients (46.0%) were classified as "trial-ineligible" and had significantly worse outcomes compared with "potentially trial-eligible" patients (n = 403, 54.0%): median progression-free survival: 6.2 (95% confidence interval [CI]: 5.2-8.4) versus 10.3 (95% CI: 8.4-13.8) months, hazard ratio (trial-ineligible versus potentially trial-eligible) of 1.43 (95% CI: 1.19-1.72), less than 0.001; median overall survival: 15.9 (95% CI: 11.4-20.3) versus 25.3 (95% CI: 19.8-30.4) months, hazard ratio of 1.36 (95% CI: 1.10-1.67), equals 0.004.

Conclusions: Our data reveal that a considerable proportion of patients with mNSCLC are not eligible to participate in a clinical trial and were found to have worse outcomes than potentially trial-eligible patients, whose outcomes were comparable with those obtained from pivotal clinical trials. This is of substantial clinical relevance for physicians discussing outcomes to be expected with their patients and stresses the need for real-world effectiveness analyses.

Citing Articles

Real-world analysis of treatment patterns and survival outcome of glioblastoma patients in a German single-center study: Can survival rates of randomized controlled trials be achieved?.

Paus S, Hoffmann J, Roeper J, Griesinger F Neurooncol Adv. 2025; 7(1):vdaf009.

PMID: 39949658 PMC: 11822374. DOI: 10.1093/noajnl/vdaf009.

Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study.

Rousseau A, Michiels S, Simon-Tillaux N, Lolivier A, Bonastre J, Planchard D Lancet Reg Health Eur. 2024; 43:100970.

PMID: 39040528 PMC: 11262181. DOI: 10.1016/j.lanepe.2024.100970.

References

Griesinger F, Eberhardt W, Nusch A, Reiser M, Zahn M, Maintz C . Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer. 2020; 152:174-184. DOI: 10.1016/j.lungcan.2020.10.012. View

Karim S, Xu Y, Kong S, Abdel-Rahman O, Quan M, Cheung W . Generalisability of Common Oncology Clinical Trial Eligibility Criteria in the Real World. Clin Oncol (R Coll Radiol). 2019; 31(9):e160-e166. DOI: 10.1016/j.clon.2019.05.003. View

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

Metzenmacher M, Griesinger F, Hummel H, Elender C, Schafer H, de Wit M . Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry. Eur Respir J. 2022; 61(2). PMC: 9892864. DOI: 10.1183/13993003.01336-2022. View

Sebastian M, Eberhardt W, Hoffknecht P, Metzenmacher M, Wehler T, Kokowski K . KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer. 2021; 154:51-61. DOI: 10.1016/j.lungcan.2021.02.005. View

Kroenke K, Spitzer R, Williams J, Lowe B . An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics. 2009; 50(6):613-21. DOI: 10.1176/appi.psy.50.6.613. View

Quan H, Li B, Couris C, Fushimi K, Graham P, Hider P . Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011; 173(6):676-82. DOI: 10.1093/aje/kwq433. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016; 389(10066):255-265. PMC: 6886121. DOI: 10.1016/S0140-6736(16)32517-X. View

10.

Smit H, Aerts J, van den Heuvel M, Hiltermann T, Bahce I, Smit E . Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry. Lung Cancer. 2020; 140:107-112. DOI: 10.1016/j.lungcan.2019.12.011. View

11.

Brahmer J, Reckamp K, Baas P, Crino L, Eberhardt W, Poddubskaya E . Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2):123-35. PMC: 4681400. DOI: 10.1056/NEJMoa1504627. View

12.

Mok T, Wu Y, Kudaba I, Kowalski D, Cho B, Turna H . Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019; 393(10183):1819-1830. DOI: 10.1016/S0140-6736(18)32409-7. View

13.

Meyers D, Pasternak M, Dolter S, Grosjean H, Lim C, Stukalin I . Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors. JTO Clin Res Rep. 2023; 4(4):100482. PMC: 10120368. DOI: 10.1016/j.jtocrr.2023.100482. View

14.

Middleton G, Brock K, Savage J, Mant R, Summers Y, Connibear J . Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. Lancet Respir Med. 2020; 8(9):895-904. DOI: 10.1016/S2213-2600(20)30033-3. View

15.

Schiller J, Harrington D, Belani C, Langer C, Sandler A, Krook J . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346(2):92-8. DOI: 10.1056/NEJMoa011954. View

16.

Hosokawa S, Ichihara E, Harada D, Kuyama S, Inoue K, Gemba K . Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801. Int J Clin Oncol. 2022; 27(7):1139-1144. DOI: 10.1007/s10147-022-02164-2. View

17.

Jimenez Galan R, Prado-Mel E, Perez-Moreno M, Caballano-Infantes E, Flores Moreno S . Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population. Biology (Basel). 2021; 10(9). PMC: 8472602. DOI: 10.3390/biology10090890. View

18.

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J Clin Oncol. 2019; 37(7):537-546. DOI: 10.1200/JCO.18.00149. View

19.

Corrigan-Curay J, Sacks L, Woodcock J . Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness. JAMA. 2018; 320(9):867-868. DOI: 10.1001/jama.2018.10136. View

20.

Cella D, Bonomi A, Lloyd S, Tulsky D, Kaplan E, Bonomi P . Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995; 12(3):199-220. DOI: 10.1016/0169-5002(95)00450-f. View